Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
LIPO 
Lipella Pharmaceuticals Inc. Common Stock (LIPO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: LIPO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $10
1 Year Target Price $10
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -29.91% | Avg. Invested days 10 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 2.74M USD | Price to earnings Ratio - | 1Y Target Price 10 |
Price to earnings Ratio - | 1Y Target Price 10 | ||
Volume (30-day avg) 1 | Beta -0.09 | 52 Weeks Range 0.55 - 4.69 | Updated Date 08/29/2025 |
52 Weeks Range 0.55 - 4.69 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.33 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-09-03 | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1564.19% |
Management Effectiveness
Return on Assets (TTM) -118.45% | Return on Equity (TTM) -248.36% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 233345 | Price to Sales(TTM) 5.83 |
Enterprise Value 233345 | Price to Sales(TTM) 5.83 | ||
Enterprise Value to Revenue 0.44 | Enterprise Value to EBITDA -4.4 | Shares Outstanding 4620840 | Shares Floating 4329355 |
Shares Outstanding 4620840 | Shares Floating 4329355 | ||
Percent Insiders 6.53 | Percent Institutions 1.35 |
Upturn AI SWOT
Lipella Pharmaceuticals Inc. Common Stock
Company Overview
History and Background
Lipella Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development of new therapies for patients with serious diseases of the bladder and urinary tract. They focus on developing solutions for unmet needs in these areas.
Core Business Areas
- Lidocaine: Developing LP-10, a proprietary intravesical formulation of lidocaine, for the treatment of acute radiation cystitis (ARC).
- Bladder Diseases: Focusing on researching and developing treatments for other serious diseases of the bladder and urinary tract.
Leadership and Structure
Bruce J. Gillis is the CEO. The company has a board of directors and a management team focused on clinical development and commercialization.
Top Products and Market Share
Key Offerings
- LP-10 (Lidocaine Formulation): LP-10 is Lipella's primary product candidate. It's an intravesical formulation of lidocaine under development for the treatment of acute radiation cystitis (ARC). Market share data is not yet applicable as it is still in development. Competitors for treating ARC include generic lidocaine and supportive care treatments.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and regulated. There is a growing demand for innovative therapies for bladder diseases due to aging populations and increasing incidence of related conditions.
Positioning
Lipella is positioned as a specialty pharmaceutical company focused on niche markets with unmet needs. Their competitive advantage lies in their proprietary formulation and targeted approach.
Total Addressable Market (TAM)
The total addressable market for ARC treatment is estimated to be in the hundreds of millions of dollars annually. Lipella is positioning LP-10 to capture a significant portion of this market with a differentiated product.
Upturn SWOT Analysis
Strengths
- Proprietary formulation of lidocaine
- Focus on unmet medical needs in bladder diseases
- Experienced management team
- Potential for Orphan Drug designation
Weaknesses
- Single product focus (LP-10)
- Reliance on clinical trial success
- Limited financial resources
- No current revenue generation
Opportunities
- Successful clinical trials leading to FDA approval
- Potential for partnerships or collaborations
- Expansion into other bladder disease indications
- Acquisition by a larger pharmaceutical company
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from existing treatments or new therapies
- Inability to secure funding
Competitors and Market Share
Key Competitors
- ENDP
- JNJ
- PFE
Competitive Landscape
Lipella faces competition from established pharmaceutical companies with broader portfolios and greater resources. However, their focused approach and proprietary formulation could provide a competitive advantage in the niche market of ARC treatment.
Growth Trajectory and Initiatives
Historical Growth: Limited historical growth due to being a development-stage company.
Future Projections: Future growth dependent on successful development and commercialization of LP-10. Analyst estimates vary widely.
Recent Initiatives: Focusing on advancing LP-10 through clinical trials and seeking regulatory approvals.
Summary
Lipella Pharmaceuticals is a development-stage company with a focus on bladder diseases, primarily developing LP-10 for ARC. Its success hinges on clinical trial outcomes and regulatory approvals. The company's strengths include its proprietary formulation, but its weaknesses are its single product focus and reliance on external funding. Investors should monitor clinical trial results and cash flow carefully.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Lipella Pharmaceuticals Inc. Website
- SEC Filings
- Industry Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. The information provided is for informational purposes only and should not be construed as a recommendation to buy or sell any security. Investing in development-stage pharmaceutical companies involves significant risks.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Lipella Pharmaceuticals Inc. Common Stock
Exchange NASDAQ | Headquaters Pittsburgh, PA, United States | ||
IPO Launch date 2022-12-19 | Co-Founder, Chairman, CEO, President, Secretary & Treasurer Dr. Jonathan Kaufman M.B.A., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 5 | Website https://lipella.com |
Full time employees 5 | Website https://lipella.com | ||
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It develops LP-10, a formulation of tacrolimus for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; LP-410, an oral liposomal formulation of tacrolimus to treat oral graft-versus-host disease; and LP-50, an intravesical formulation of immunoglobulins for the treatment of non-muscle invasive bladder cancer. Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.